Guotai SSE STAR Brand Name Drug ETF

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

BeiGene's Brukinsa Approved by FDA

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

Belayidiantianheng Receives Approval for Clinical Trials of Iza-bren Combination Therapy

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeOne Medicines released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue CNY 10.46 B (forecast CNY 9.93 B), actual EPS CNY 1.0368

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

Chemexpress released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 728.65 M, actual EPS CNY 0.32

BrightGene released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 324.93 M, actual EPS CNY 0.02

BeOne Medicines to Release FY2026 Q1 Earnings on May 6 Pre-Market (BJT), Forecast Revenue CNY 9.835 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

01801

159316

159570

516930

510660

513120

159615

159849

588130

512290

512010

589720

159837

159892

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

ZLAB

09688

159929

562050

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

Ping An CSI Medicine and Medical Device Innovation ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

01833

516610

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

AASTOCKS News

PA GOODDOCTOR

Dacheng CSI All Share Health Care Equipment and Services ETF

CICC

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

01889

Sanai Health Industry Group has been ordered by the High People’s Court of Beijing to pay approximately RMB120 million in a finance lease dispute involving its subsidiary, Fujian Sanai. The judgment includes principal, interest, and legal fees, with the company and two individuals held jointly liable. While this litigation will impact the company's cash reserves and net assets, Sanai Health has sufficient funds to cover the judgment. The management is evaluating the effects on its 2026 financial statements and plans to seek compensation from other parties involved.

Tip Ranks

SANAI HEALTH GP

Sanai Health Hit With Final RMB120 Million Judgment in Beijing Lease Dispute

00241

ALI HEALTHreported a net profit of RMB1.94 billion for the year ending March 31, 2026, marking a 35.2% increase year-on-year. Revenue rose to RMB34.255 billion, up 12% YoY, with an EPS of RMB12.02 cents. The company declared a total dividend of RMB19.47 cents, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents.

ALI HEALTH

ALI HEALTH Annual Net Profit RMB1.94B, Up 35.2% YoY; Final & Spec. Div. Total RMB19.47 Cents

SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.

SPDR S&P Biotech

Ark Genomic Revolution ETF

Proshares UltraShort Nasdaq Biotech

ICBCCS SSE STAR Biology and Medicine ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SBP GROUP

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Innovent Biologics, Inc. will present clinical and preclinical results of mazdutide and its next-generation obesity and metabolic pipeline at the 2026 ADA Scientific Sessions in New Orleans from June 5-8, 2026. Key presentations include studies on mazdutide's efficacy in adults and adolescents with obesity and type 2 diabetes, highlighting its profile as a GCG/GLP-1 dual receptor agonist. The pipeline also features innovative oral GLP-1 receptor agonists and an amylin analog aimed at addressing obesity-related challenges. This event marks a significant step for Innovent in establishing leadership in obesity and metabolic disease treatment.

Unusual Whales

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

StockTitan

BlackRock, Inc.

iShares Global Healthcare

Bosera Hang Seng Health Care ETF(QDII)

Health Care Select Sector SPDR

iShares US Pharma

VG Health

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

159883

159898

The DOJ has initiated a criminal investigation into NYU Langone Health regarding its provision of gender-affirming care for transgender youth. This marks the first known instance of such a probe targeting a hospital for this type of care. NYU Langone received a grand jury subpoena seeking information about minor patients and hospital staff involved in providing this care. The investigation follows a trend of increased scrutiny on transgender rights under the Trump administration, with over 20 subpoenas issued to various hospitals nationwide, leading many to halt gender-affirming treatments for young patients.

Yahoo Finance

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Healthcare Providers

iShares US Medical Devices

SPDR S&P Health

SPDR S&P Health Equip

DOJ Launches Criminal Probe Into Blue State Hospital

02509

603259

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi Biologics

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

WUXI XDC

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Guotai SSE STAR Brand Name Drug ETF(589720.SH)

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

STOCKS | Hong Kong's Innovative Drug Sector Declines

CICC Initiates PA GOODDOCTOR with Outperform Rating, TP HKD14.2

Sanai Health Hit With Final RMB120 Million Judgment in Beijing Lease Dispute

ALI HEALTH Annual Net Profit RMB1.94B, Up 35.2% YoY; Final & Spec. Div. Total RMB19.47 Cents